BioHarvest Sciences Inc.

iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.

GenScript1548.HK · BiotechChina

63% matchPublicAI 33/100 ▲Green 5/100 ▼

Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.

Bloom Labs Bio Inc. specializes in the development and manufacturing of biologics, biosimilars, recombinant proteins, monoclonal antibodies, prebiotics, and probiotics. Utilizing modern biotechnology platforms and advanced infrastructure, the company serves the pharmaceutical and life sciences sectors with therapeutic and health and wellness solutions.

Wuhan Healthgen Biotechnology Corp. develops and manufactures plant-derived recombinant human serum albumin and related biopharmaceutical materials. Its products serve biopharmaceutical manufacturers, including applications in cell culture, drug formulation, vaccines, and diagnostics.

AMYRIS, INC.BiotechnologyUnited States

63% matchPrivate

Amyris, Inc. is a vertically integrated biomanufacturing company that converts plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products using precision fermentation.

Bora6472 · PharmaceuticalsTaipei City, Taiwan

63% matchPublic

Globally, Bora Pharmaceuticals Co., LTD. is engaged in the comprehensive lifecycle of pharmaceutical products, encompassing research and development, manufacturing, distribution, and sales. The organization operates through key divisions, including Sales, Contract Development & Manufacturing Organization (CDMO), and other ancillary services. Bora produces and markets a diverse range of medicines, from generic and proprietary brand-name drugs to over-the-counter (OTC) remedies. Beyond its in-house portfolio, the company provides extensive contract development and manufacturing solutions. These CDMO services cover all stages of pharmaceutical development, clinical and commercial production, specialized packaging and serialization, rigorous analytical and microbiological quality control, and expert guidance on regulatory compliance. Furthermore, Bora's offerings extend to nutritional supplements, skincare products, and various biotechnical services. The company distributes its goods directly to healthcare facilities such as clinics, pharmacies, and pharmacy chains, as well as to drugstores. It also leverages distributors to supply larger institutions like medical centers, corporate and public hospitals, and regional and district hospitals. Established in 2007, Bora Pharmaceuticals Co., LTD. is based in Taipei City, Taiwan.